Compare Citius Pharmaceuticals Inc (CTXR) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs TKO Group Holdings Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while TKO Group Holdings Inc trades at $195.16 (market cap $14.24B). The key difference: TKO Group Holdings Inc is far larger — about 711.6× Citius Pharmaceuticals Inc's market cap, and TKO Group Holdings Inc pays a 1.6% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | TKO | |
|---|---|---|
Market Cap | $20.01M | $14.24B |
Sector | Health | Technology |
52-Week High | $1.82 | $224.96 |
52-Week Low | $0.48 | $176.49 |
Enterprise Value | $16.23M | $18.60B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
TKO trades at $195.15, up 3.03% today, with a bullish technical outlook supported by moving averages and strong institutional sentiment. The stock shows robust revenue growth, with Q2 2026 revenue reaching $1.55 billion (up 18% year-over-year, Business Wire, August 3, 2026), and raised full-year guidance. However, a high P/E ratio of 68.33 and mixed quarterly EPS results highlight valuation concerns amid solid operational performance.
The outlook remains positive due to strong media rights and live event momentum, but risks include earnings volatility and competitive pressures. Analyst consensus is strongly bullish with a $228.17 price target, suggesting ~17% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
